INDIANAPOLIS and CAIRO, Sept. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today that the companies have entered into an agreement to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. Discovered by Incyte and licensed to Lilly, baricitinib is for the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19..

印第安纳波利斯和开罗，2024年9月4日/PRNewswire/--礼来公司（纽约证券交易所：LLY）和长荣制药今天宣布，两家公司已达成协议，到2030年，将非洲49个中低收入国家的约20000人获得巴利替尼。baricitinib由Incyte发现并授权给礼来，用于治疗类风湿性关节炎、斑秃、特应性皮炎和新型冠状病毒。。

This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030.

这项合作是礼来30x30计划的一部分，该计划旨在到2030年，每年为生活在资源有限环境中的3000万人提供优质医疗服务。

'Our commitment to expanding access to affordable and innovative medicines for people living in low- to middle-income countries continues,' said Ilya Yuffa, executive vice president and president of Lilly International. 'Following our collaboration with EVA Pharma on insulin manufacturing, we are now establishing the first of its kind voluntary licensing agreement for Lilly, where the company will provide certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply baricitinib to people in 49 countries across Africa.' .

礼来国际执行副总裁兼总裁伊利亚·尤法（IlyaYuffa）说，我们继续致力于扩大中低收入国家人民获得负担得起的创新药物的机会。

'We are proud to localize the entire value chain of this critical medication on the continent, from producing high-potency baricitinib active pharmaceutical ingredient (API), to tackling complex manufacturing challenges,' said Riad Armanious, CEO of EVA Pharma.

EVA Pharma首席执行官里亚德·阿马尼奥斯（Riad Armanious）说：“我们很自豪地将这种关键药物的整个价值链本地化，从生产高效巴利替尼活性药物成分（API）到应对复杂的制造挑战。”。

EVA Pharma's dedicated high-containment facility is set to begin sales of the locally manufactured baricitinib by 2026 to various African countries.

长荣制药（EVA Pharma）的专用高遏制设施将于2026年开始向非洲各国销售当地生产的巴利替尼。

This collaboration announced today relies on both EVA's pan-African reach and its strong local manufacturing capabilities that meet global standards, enabling Lilly to reach more people in low- to middle-income countries.

今天宣布的这项合作既依赖于长荣的泛非影响力，也依赖于其强大的符合全球标准的当地制造能力，使礼来能够接触到中低收入国家的更多人。

Since 2021, EVA Pharma has been working with Lilly to ensure a sustainable supply of life-saving medicines across several African countries. Lilly and EVA Pharma are also collaborating to expand access to affordable insulin in 56 countries, most of which are low- to middle-income, as announced in 2022..

自2021年以来，长荣制药一直与礼来合作，以确保在几个非洲国家可持续供应救生药物。礼来和长荣制药也在合作，以扩大在56个国家获得负担得起的胰岛素的机会，其中大多数是中低收入国家，如2022年宣布的那样。。

About Lilly

关于礼来

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家将科学转化为治疗的医药公司，旨在让世界各地的人们生活得更好。近150年来，我们一直在开创改变生活的发现，今天，我们的药物帮助了全球5100多万人。利用生物技术、化学和遗传医学的力量，我们的科学家正在迫切推进新发现，以解决世界上一些最重大的健康挑战：重新定义糖尿病护理；治疗肥胖并减少其最具破坏性的长期影响；推进与阿尔茨海默病的斗争；为一些最致命的免疫系统疾病提供解决方案；。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. C-LLY.

在迈向更健康世界的每一步中，我们都有一个动机：让数百万人的生活变得更好。这包括提供反映我们世界多样性的创新临床试验，并努力确保我们的药物可获得且负担得起。要了解更多信息，请访问Lilly.com和Lilly.com/news，或在Facebook、Instagram和LinkedIn上关注我们。C-LLY公司。

About EVA Pharma

关于EVA Pharma

EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies..

EVA Pharma 致力于为全球社区的健康和福祉而奋斗。公司拥有一支 5000 多人的专业团队，其先进的生产设施每天生产 100 多万种保健产品，这些设施配备了尖端技术，因其创新性而得到国际认可，并已获得多个监管机构的批准。

The company's product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.

公司的产品组合主要集中在糖尿病和心血管疾病、肿瘤、神经科学、眼科、抗感染、骨与疼痛、肝病和生殖健康等急需但尚未得到满足的疾病领域，以满足本地和国际需求。

EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.

长荣制药（EVA Pharma）是中东和非洲发展最快的医疗保健公司之一，拥有广泛的泛非业务，在全球40多个国家开展业务。